Merrimack Pharmaceuticals, Inc.
MACK · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $445 | $0 | $0 |
| Gross Profit | $0 | -$445 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $2,176 | $2,174 | $2,616 | $5,012 |
| SG&A Expenses | $2,176 | $2,174 | $2,616 | $5,012 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,176 | $2,174 | $2,616 | $5,012 |
| Operating Income | -$2,176 | -$1,729 | -$2,472 | -$2,873 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,007 | $633 | $164 | $1,998 |
| Pre-Tax Income | -$1,169 | -$1,541 | -$2,452 | -$3,014 |
| Tax Expense | $12 | $3 | $3 | $14 |
| Net Income | -$1,181 | -$1,544 | -$2,455 | -$3,028 |
| % Margin | – | – | – | – |
| EPS | -0.083 | -0.11 | -0.18 | -0.23 |
| % Growth | 24.9% | 38.9% | 21.7% | – |
| EPS Diluted | -0.083 | -0.11 | -0.18 | -0.23 |
| Weighted Avg Shares Out | 14,299 | 13,524 | 13,407 | 13,380 |
| Weighted Avg Shares Out Dil | 14,299 | 13,524 | 13,407 | 13,380 |
| Supplemental Information | – | – | – | – |
| Interest Income | $868 | $188 | $20 | $50 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $168 | -$890 | -$288 | -$2,280 |
| EBITDA | $1,007 | -$2,619 | -$2,760 | -$5,153 |
| % Margin | – | – | – | – |